Canine Bone Marrow Stromal Cells Promote Functional Recovery in Mice with Spinal Cord Injury

Yasutaka ODA1,2, Kenji TANI3*, Yusuke ASARI2, Luiz Fernando QUINTANILHA3, Tomoya HARAGUCHI4, Yutaka MOMOTA5, Masaaki KATAYAMA6, Kazuhito ITAMOTO4, Hiroshi NAKAZAWA2 and Yasuho TAURA2

1)The United Graduate School of Veterinary Science, Yamaguchi University, 1677–1 Yoshida, Yamaguchi 753–8515, Japan
2)Department of Veterinary Surgery, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677–1 Yoshida, Yamaguchi 753–8515, Japan
3)Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1–1–1 Ube, Yamaguchi 755–8505, Japan
4)Animal Medical Center, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677–1 Yoshida, Yamaguchi 753–8515, Japan
5)Department of Veterinary Nursing and Technology, Nippon Veterinary and Life Science University, 1–7–1 Kyonan-cho, Musashino, Tokyo 180–8602, Japan
6)Division of Small Animal Surgery, Department of Veterinary Science, Faculty of Agriculture, Iwate University, 3–18–8 Ueda, Morioka, Iwate 020–8550, Japan

(Received 23 November 2013/Accepted 7 February 2014/Published online in J-STAGE 21 February 2014)

NOTE

Surgery

Despite progress in the treatment of spinal cord injury (SCI), recovery from severe paralysis remains difficult. Several cell types, including embryonic spinal cord stem cells [10], Schwann cells [12], olfactory ensheathing glia [11] and bone marrow-derived cells [14], have been used in transplant aims at spinal cord regeneration. Bone marrow stromal cells (BMSCs) are adherent, non-hematopoietic cells obtained from culturing bone marrow aspirates [14]. Canine BMSCs are technically easy to isolate and expand [7]. The most significant practical advantages of using BMSCs are the capability of autologous transplantation, low cost of culturing and very low risk of teratoma formation [14]. Recently, spinal cord regenerative therapy using bone marrow-derived cells has begun to be clinically applied, leading to promising results in human and veterinary medicine [1, 13, 16]. However, the mechanism of the effects of these cell sources and the cells that are the most effective remain unknown. In the present study, we employed a SCI model to investigate the efficacy of canine BMSC treatment for improving locomotor function in immunosuppressed mice. Bone marrow cells were collected from the humeri and femora of a clinically healthy dog (2-year-old male Beagle) under anesthesia. The animal received humane care in compliance with the guidelines for treatment of experimental animals at Yamaguchi University. The bone marrow cells were seeded onto NunclonΔSurface (NUNC, Thermo Fisher Scientific Inc., Waltham, MA, U.S.A.) and cultured in Dulbecco’s modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA, U.S.A.) and supplemented with 10% fetal bovine serum, 2.5 µg/ml amphotericin B in a 5% CO2 incubator at 37°C. After 2 days, non-adherent cells were washed away with medium. The adherent cells were used as canine BMSCs. The culture medium was changed twice a week, and cells in the second or third passage were used. During subculture, flow cytometry analyses were performed utilizing Gallios equipment (Beckman Coulter, Inc., Brea, CA, U.S.A.). Propidium iodide (Sigma-Aldrich, Steinheim, Germany) was used to exclude dead cells from analyses. Data were analyzed using Kaluza software (Beckman Coulter). Monoclonal antibodies against CD11b (AbD serotec, Oxford, U.K.), CD29-PE (Abcam, Cambridge, U.K.), CD44-PE-Cy7 (Biolegend, San Diego, CA, U.S.A.), CD45-e-fluor eBioscience, Inc., San Diego, CA, U.S.A.) and CD90-APC eBioscience were used in this study. Secondary detection of the CD11b antibody was performed using goat polyclonal secondary antibody to mouse IgG-H&L (DyLight® 488) (Abcam). Isotype-identical antibodies (IgGs) were used as

*CORRESPONDENCE TO: TANI, K., Department of Veterinary Surgery, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677–1 Yoshida, Yamaguchi 753–8515, Japan. e-mail: ktani@yamaguchi-u.ac.jp

©2014 The Japanese Society of Veterinary Science

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.
negative controls.

The surface of cells was positive for CD29, CD44 and CD90 and negative for CD11b and CD45 (Fig. 1A). To confirm the differentiation potential, canine BMSCs were grown in osteogenic and adipogenic differentiation media (Cyagen Biosciences, Inc., Santa Clara, CA, U.S.A.) according to the manufacturer’s instructions. After 2 weeks, deposition of bone mineral was observed following alizarin red staining (pH 4.3; AppliChem, Chicago, IL, U.S.A.) (Fig. 1B). Cells containing lipid droplets were observed following OilRed O staining (Sigma–Aldrich) (Fig. 1B).

The SCI model was performed using female severe combined immunodeficiency mice (n=24). Mice were anesthetized with pentobarbital (50 mg/kg, i.p.), a dorsal laminectomy was performed at the T10 level, and the exposed spinal cord was completely transected with a surgical knife. The animals were divided into 2 groups that were treated with BMSCs or DMEM (control). Cell transplantation was performed immediately after SCI by infusing 1 × 10⁵ cells/µl in 12 µl DMEM using a Hamilton syringe (Hamilton Co., Reno, NV, U.S.A.) into six points rostral and six points caudal to the injury site (1 µl per location for a total of 12 µl per animal). Before transplantation, canine BMSCs were labeled using a carboxyfluorescein diacetate-succinimidyl ester cell tracer kit (Invitrogen) according to the manufacturer’s instructions. The labeled cells were washed three times and resuspended in DMEM. Cell labeling was confirmed by fluorescent microscope observation.

Motor functional evaluation was performed for each hind limb at 1–4 weeks post-SCI using the Basso-Beattie-Bresnahan (BBB) Locomotor Rating Scale [2]. Significant increases in BBB scores in the BMSC group compared to the control were observed at 1–4 weeks post-SCI.

At 4 weeks post-SCI, genomic DNA was prepared from the spinal cord homogenate of 2 mice per group using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). The presence or absence of the sex determination region on the male Y chromosome (SRY) in recipient female mice was assessed with PCR. Primer sequences for SRY were obtained from published sequences (AF107021; forward primer, 5’-CAAGATGGCTCTAGAATCCC-3′; reverse primer, 5’-AGCGTGTCCGTGTAGGTGA-3′) and amplified a product of 284 bp. The PCR conditions were as follows: incubation at 94°C for 2 min; 40 cycles of incubation at 94°C for 30 sec, 57°C for 30 sec and 72°C for 30 sec. PCR products were separated using 2% agarose gel electrophoresis, and gels were stained with ethidium bromide.

Four weeks post-SCI, the remaining mice in each group were deeply anesthetized with pentobarbital (100 mg/kg, i.p.) and perfused transcardially with Zamboni solution. The lesion region, including adjacent intact areas of the spinal cord, was excised, immersed in Zamboni solution overnight and cryoprotected by immersion in a series of sucrose solutions (10%, 15% and 20% sucrose in 0.1 M PBS) at 4°C. The tissues were then frozen, embedded in OCT compound (Sakura Finetek Co., Ltd., Tokyo, Japan), sectioned longitudinally at 8 µm thickness using a cryostat and mounted on (3-aminopropyl) trimethoxysilane (APS)-coated slides for use in immunohistochemical analysis. Primary antibodies for microtubule-associated protein-2 (MAP-2; Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.) (1:100) and nestin (Santa Cruz Biotechnology) (1:100) were used in this study.

Canine BMSCs used in this study were CD29⁺, CD44⁺, CD90⁺, CD11b⁻ and CD45⁻ (Fig. 1A) as reported in previous studies [7, 15]. The canine BMSCs showed adipogenic and osteogenic multi-differentiation potential (Fig. 1B). We [13] and other authors [6] previously reported that canine BMSCs differentiate into neuronal cells. Thus, canine BMSCs were confirmed to be capable of differentiation into not only mesoblast-derived cells but also into ectoblast-derived cells, as reported for other species in previous studies.

Although this study was not a double-blind design, canine BMSC transplantation enhanced the functional recovery of the hind limbs in mice with SCI (Fig. 2). Similar functional recoveries were observed in previous reports with other species using different contusion SCI model [4, 8] which were most common type of SCI. The role of transplanted BMSCs remains to be elucidated. Several studies have reported that BMSCs have indirect neuroprotective effects due to secretion of neurotrophic or growth factors, including basic fibroblast growth factor, nerve growth factor, brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor and insulin-like growth factor 1 [5, 9]. Transplanted BMSCs integrate into the host spinal cord and contribute to rebuilding of axons and axonal function [5]. Moreover, about 30% of the BMSCs acquire a neuronal phenotype without evidence of cell fusion when co-cultured with neurons [9]. BMSCs can also acquire electrophysiological functions similar to neurons in vitro and express neuron-specific receptors [20]. The engrafted BMSCs degrade the extracellular matrix in the glial scar by secreting several proteases, such as matrix metalloproteases, to promote neurite outgrowth from spinal cord neurons [17]. Thus, transplanted BMSCs may play an indirect neuroprotective role through multiple mechanisms. Transplanted cells in this study were detected in SCI lesion site (T10) and lumbar cord in mice at genomic level (Fig. 3A) and histologically near the glial scar around the lesion site at least 4 weeks after treatment (Fig. 3B). PCR amplification was more sensitive than fluorescence staining.

Nestin-positive cells were morphologically fibroblastic, differed from the transplanted cells, and were not observed close to the fluorescently labeled transplanted BMSCs in this study (Fig. 4). Thus, transplanted BMSCs may not differentiate into cells with neuronal phenotypes in mice with SCI. Nestin is an intermediate filament protein and a widely employed marker of multipotent neural stem cells [18, 19]. On the other hand, reactive astrocytes are rather beneficial in promoting neuronal survival by releasing many trophic factors and expressing stem cell markers, such as nestin [3]. Thus, the nestin-positive cells might be derived from reactive astrocytes. Nestin-positive cells in the scar tissue may be associated with the functional recovery of the hind limbs in SCI mice, although the in vivo physiological function of nestin remains unknown.

The xenotransplantation model used in this study may not necessarily reflect SCI in canines; however, this model may
establish a certain standard to evaluate the most effective cell sources, the number of cells required for treatment, the timing of transplantation and other factors.

REFERENCES

1. Azari, M. F., Mathias, L., Ozturk, E., Cram, D. S., Boyd, R. L. and Petratos, S. 2010. Mesenchymal stem cells for treatment of CNS injury. Curr. Neuropharmacol. 8: 316–323. [Medline] [CrossRef]

2. Basso, D. M., Beattie, M. S. and Bresnahan, J. C. 1995. A sensi-
tive and reliable locomotor rating scale for open field testing in rats. *J. Neurotrauma* **12**: 1–21. [Medline] [CrossRef]

3. Buffò, A., Rite, I., Tripathi, P., Lepier, A., Colak, D., Horn, A. P., Mori, T. and Gotz, M. 2008. Origin and progeny of reactive gliosis: A source of multipotent cells in the injured brain. *Proc. Natl. Acad. Sci. U.S.A.* **105**: 3581–3586. [Medline] [CrossRef]

4. Chiba, Y., Kuroda, S., Maruichi, K., Osanai, T., Hokari, M., Yano, S., Shichinohe, H., Hida, K. and Iwasaki, Y. 2009. Transplanted bone marrow stromal cells promote axonal regeneration and improve motor function in a rat spinal cord injury model. *Neurosurgery* **64**: 991–999. [Medline] [CrossRef]

5. Chiba, Y., Kuroda, S., Shichinohe, H., Hokari, M., Osanai, T., Maruichi, K., Yano, S., Hida, K. and Iwasaki, Y. 2010. Synergistic effects of bone marrow stromal cells and a Rho kinase (ROCK) inhibitor, fasudil on axon regeneration in rat spinal cord injury. *Neuropharmacology* **30**: 241–250. [Medline] [CrossRef]

6. Edamura, K., Kuriyama, K., Kato, K., Nakano, R., Teshima, K., Asano, K., Sato, T. and Tanaka, S. 2012. Proliferation capacity, neuronal differentiation potency and microstructures after the differentiation of canine bone marrow stromal cells into neurons. *J. Vet. Med. Sci.* **74**: 923–927. [Medline] [CrossRef]

7. Haraguchi, T., Tani, K., Takagishi, R., Oda, Y., Itamoto, K., Yamamoto, N., Terai, S., Sakaida, I., Nakazawa, H. and Taura, Y. 2012. Therapeutic potential of canine bone marrow stromal cells (BMSCs) in the carbon tetrachloride (CCl4) induced chronic liver dysfunction mouse model. *J. Vet. Med. Sci.* **74**: 607–611. [Medline] [CrossRef]

8. Himes, B. T., Neuhuber, B., Coleman, C., Kushner, R., Swanger, S. A., Kopen, G. C., Wagner, J., Shumsky, J. S. and Fischer, I. 2006. Recovery of function following grafting of human bone marrow-derived stromal cells into the injured spinal cord. *Neurorehabil. Neural Repair* **20**: 278–296. [Medline] [CrossRef]

9. Hokari, M., Kuroda, S., Shichinohe, H., Yano, S., Hida, K. and Iwasaki, Y. 2008. Bone marrow stromal cells protect and repair damaged neurons through multiple mechanisms. *J. Neurosci. Res.* **86**: 1024–1035. [Medline] [CrossRef]

10. Iwashita, Y., Kawaguchi, S. and Murata, M. 1994. Restoration of function by replacement of spinal cord segments in the rat. *Nature* **367**: 167–170. [Medline] [CrossRef]

11. Li, Y., Field, P. M. and Raisman, G. 1997. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. *Science* **277**: 2000–2002. [Medline] [CrossRef]

12. Martin, D., Robe, P., Franzen, R., Deltree, P., Schoenen, J., Stevenaert, A. and Moonen, G. 1996. Effects of Schwann cell transplantation in a contusion model of rat spinal cord injury. *J. Neurosci. Res.* **45**: 588–597. [Medline] [CrossRef]

13. Nishida, H., Nakayama, M., Tanaka, H., Kitamura, M., Hatoya, S., Sugiura, K., Harada, Y., Suzuki, Y., Ide, C. and Inaba, T. 2012. Safety of autologous bone marrow stromal cell transplantation in dogs with acute spinal cord injury. *Vet. Surg.* **41**: 437–442. [Medline] [CrossRef]

14. Ohta, M., Suzuki, Y., Noda, T., Ejiri, Y., Dezawa, M., Kataoka, K., Chou, H., Ishikawa, N., Matsumoto, N., Iwashita, Y., Mizuta, E., Kuno, S. and Ide, C. 2004. Bone marrow stromal cells infused into the cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation. *Exp. Neurol.* **187**: 266–278. [Medline] [CrossRef]

15. Pastor, D., Viso-Leon, M. C., Jones, J., Jaramillo-Merchan, J., Toledo-Aral, J. J., Moraleda, J. M. and Martinez, S. 2012. Comparative effects between bone marrow and mesenchymal stem cell transplantation in GDFN expression and motor function recovery in a motorneuron degenerative mouse model. *Stem Cell Rev.* **8**: 445–458. [Medline] [CrossRef]

16. Saito, F., Nakatani, T., Iwase, M., Maeda, Y., Murao, Y., Suzuki, Y., Fukushima, M. and Ide, C. 2012. Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: a pilot study. *Restor. Neurol. Neurosci.* **30**: 127–136. [Medline] [CrossRef]

17. Sarnowska, A., Braun, H., Sauerweig, S. and Reynmann, K. G. 2009. The neuroprotective effect of bone marrow stem cells is not dependent on direct cell contact with hypoxic injured tissue. *Exp. Neurol.* **215**: 317–327. [Medline] [CrossRef]

18. Walker, A. S., Goings, G. E., Kim, Y., Miller, R. J., Chen, A. and Szelle, F. G. 2010. Nestin reporter transgene labels multiple central nervous system precursor cells. *Neural Plast.* **2010**: 894374. [Medline] [CrossRef]

19. Wiese, C., Rolletschek, A., Kania, G., Blyszczuk, P., Tarasov, K. V., Tarasova, Y., Wersto, R. P., Boheler, K. R. and Wobus, A. M. 2004. Nestin expression–a property of multi-lineage progenitor cells? *Cell. Mol. Life Sci.* **61**: 2510–2522. [Medline] [CrossRef]

20. Yano, S., Kuroda, S., Shichinohe, H., Seki, T., Ohnishi, T., Tamagami, H., Hida, K. and Iwasaki, Y. 2006. Bone marrow stromal cell transplantation preserves gammaaminobutyric acid receptor function in the injured spinal cord. *J. Neurotrauma* **23**: 1682–1692. [Medline] [CrossRef]